1. Home
  2. ALT vs SOR Comparison

ALT vs SOR Comparison

Compare ALT & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • SOR
  • Stock Information
  • Founded
  • ALT 1997
  • SOR 1968
  • Country
  • ALT United States
  • SOR United States
  • Employees
  • ALT N/A
  • SOR N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • SOR Investment Managers
  • Sector
  • ALT Health Care
  • SOR Finance
  • Exchange
  • ALT Nasdaq
  • SOR Nasdaq
  • Market Cap
  • ALT 292.0M
  • SOR 364.9M
  • IPO Year
  • ALT N/A
  • SOR N/A
  • Fundamental
  • Price
  • ALT $3.83
  • SOR $44.50
  • Analyst Decision
  • ALT Strong Buy
  • SOR
  • Analyst Count
  • ALT 6
  • SOR 0
  • Target Price
  • ALT $17.40
  • SOR N/A
  • AVG Volume (30 Days)
  • ALT 3.0M
  • SOR 16.2K
  • Earning Date
  • ALT 08-12-2025
  • SOR 01-01-0001
  • Dividend Yield
  • ALT N/A
  • SOR 7.24%
  • EPS Growth
  • ALT N/A
  • SOR N/A
  • EPS
  • ALT N/A
  • SOR 6.50
  • Revenue
  • ALT $20,000.00
  • SOR N/A
  • Revenue This Year
  • ALT N/A
  • SOR N/A
  • Revenue Next Year
  • ALT $761,880.20
  • SOR N/A
  • P/E Ratio
  • ALT N/A
  • SOR $6.41
  • Revenue Growth
  • ALT N/A
  • SOR N/A
  • 52 Week Low
  • ALT $2.90
  • SOR $36.41
  • 52 Week High
  • ALT $11.16
  • SOR $42.75
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • SOR 63.93
  • Support Level
  • ALT $3.35
  • SOR $43.65
  • Resistance Level
  • ALT $3.66
  • SOR $44.86
  • Average True Range (ATR)
  • ALT 0.19
  • SOR 0.63
  • MACD
  • ALT 0.07
  • SOR 0.05
  • Stochastic Oscillator
  • ALT 86.18
  • SOR 68.46

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About SOR Source Capital Inc.

Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.

Share on Social Networks: